NLRP3 Inflammasome Pharmacological Inhibitors in Glycyrrhiza for NLRP3-Driven Diseases Treatment: Extinguishing the Fire of Inflammation

被引:16
|
作者
Wang, Zhilei [1 ]
Xu, Guang [2 ,3 ]
Li, Zhiyong [4 ]
Xiao, Xiaohe [2 ,3 ]
Tang, Jianyuan [1 ]
Bai, Zhaofang [2 ,3 ]
机构
[1] Hosp Chengdu Univ Tradit Chinese Med, TCM Regulating Metab Dis Key Lab Sichuan Prov, Chengdu, Peoples R China
[2] Peoples Liberat Army Gen Hosp, Senior Dept Hepatol, Med Ctr 5, Beijing, Peoples R China
[3] Peoples Liberat Army Gen Hosp, China Mil Inst Chinese Mat, Med Ctr 5, Beijing, Peoples R China
[4] Chengdu Univ Tradit Chinese Med, State Key Lab Southwestern Chinese Med Resources, Chengdu, Peoples R China
基金
中国国家自然科学基金;
关键词
NLRP3; inflammasome; Glycyrrhiza; inflammatory diseases; anti-inflammatory; NF-KAPPA-B; ACUTE LIVER-INJURY; ACUTE LUNG INJURY; OXIDATIVE STRESS; NRF2; PATHWAY; ISOLIQUIRITIGENIN; LICORICE; PATHOGENESIS; PROTECTS; LIQUIRITIGENIN;
D O I
10.2147/JIR.S344071
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Inflammation is the tissues' defense response after the body is stimulated by microbial infection or damage signals, and it is initiated when pattern recognition receptors recognize pathogen-related molecular patterns and danger-related molecular patterns. The hyperactivation of NLRP3 inflammasome, the main driving force of immune outbreaks, is involved in a wide range of inflammatory diseases. Meanwhile, growing evidence has indicated that the development of NLRP3-targeted therapies offers great potential and promise for the treatment of related diseases. The search for and development of efficacious anti-inflammatory prodrugs from natural sources of plants and traditional Chinese medicines (TCMs) have received extensive attention. Glycyrrhiza, an important minister in the kingdom of TCMs, has high activity and a wide range of therapeutic effects. Studies have shown that a variety of active components found in Glycyrrhiza, such as licochalcone A, echinatin, isoliquiritigenin, and glycyrrhizin, produce a wide range of anti-inflammatory effects by discouraging NLRP3 inflammasome activation. Here, we summarize the role and mechanism of the active ingredients in Glycyrrhiza that target the NLRP3 inflammasome and treat related inflammatory diseases. We describe a favorable approach for the development of natural, safe, and efficient drugs that exploit these naturally occurring active ingredients to treat NLRP3-driven diseases.
引用
收藏
页码:409 / 422
页数:14
相关论文
共 50 条
  • [41] NLRP3 inflammasome: A likely target for the treatment of allergic diseases
    Xiao, Yichen
    Xu, Wenna
    Su, Wenru
    CLINICAL AND EXPERIMENTAL ALLERGY, 2018, 48 (09): : 1080 - 1091
  • [42] A natural product inhibitor of the NLRP3 inflammasome derived from Glycyrrhiza uraknsis for the treatment of inflammatory diseases
    Yang, Gabsik
    Lee, Hye Eun
    Han, Sin-Hee
    An, Tae-Jin
    Jang, Jae-Ki
    Lee, Joo Young
    JOURNAL OF IMMUNOLOGY, 2017, 198 (01):
  • [43] NLRP3 inflammasome and its inhibitors: a review
    Shao, Bo-Zong
    Xu, Zhe-Qi
    Han, Bin-Ze
    Su, Ding-Feng
    Liu, Chong
    FRONTIERS IN PHARMACOLOGY, 2015, 6
  • [44] NLRP3 inflammasome in cancer and metabolic diseases
    Sharma, Bhesh Raj
    Kanneganti, Thirumala-Devi
    NATURE IMMUNOLOGY, 2021, 22 (05) : 550 - 559
  • [45] Targeting the NLRP3 inflammasome in inflammatory diseases
    Mangan, Matthew S. J.
    Olhava, Edward J.
    Roush, William R.
    Seidel, H. Martin
    Glick, Gary D.
    Latz, Eicke
    NATURE REVIEWS DRUG DISCOVERY, 2018, 17 (08) : 588 - 606
  • [46] The role of the NLRP3 inflammasome in pulmonary diseases
    Hosseinian, Nima
    Cho, Young
    Lockey, Richard F.
    Kolliputi, Narasaiah
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2015, 9 (04) : 188 - 197
  • [47] NLRP3 inflammasome in cardiovascular diseases: an update
    Mo, Binhai
    Ding, Yudi
    Ji, Qingwei
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [48] Research progress of NLRP3 inflammasome and its inhibitors with aging diseases
    Yuan, Zhuo
    Yu, Dongke
    Gou, Tingting
    Tang, Guoyuan
    Guo, Chun
    Shi, Jianyou
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2023, 957
  • [49] MCC950 is a potent and specific inhibitor of the NLRP3 inflammasome and a novel potential therapeutic for NLRP3 driven diseases
    Coll, Rebecca C.
    Robertson, Avril A. B.
    Chae, Jae Jin
    Higgins, Sarah C.
    Dungan, Lara S.
    Munoz-Planillo, Raul
    Monks, Brian G.
    Croker, Daniel E.
    Sutton, Caroline E.
    Stutz, Andrea
    Nunez, Gabriel
    Latz, Eicke
    Kastner, Daniel L.
    Mills, Kingston H. G.
    Masters, Seth L.
    Schroder, Kate
    Cooper, Matt A.
    O'Neill, Luke A. J.
    CYTOKINE, 2014, 70 (01) : 35 - 35
  • [50] A novel dual NLRP1 and NLRP3 inflammasome inhibitor for the treatment of inflammatory diseases
    Docherty, Callum A. H.
    Fernando, Anuruddika J.
    Rosli, Sarah
    Lam, Maggie
    Dolle, Roland E.
    Navia, Manuel A.
    Farquhar, Ronald
    La France, Danny
    Tate, Michelle D.
    Murphy, Christopher K.
    Rossi, Adriano G.
    Mansell, Ashley
    CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2023, 12 (06)